.Discuss the pathophysiology and diagnosis of a case of pheochromocytoma. Give an account of preparation monitoring and anesthetic management of a 25 years old patient suffering from pheochromocytoma. For md anaesthesia exam .

Reading File

Finding Sources

Reading File

Searching PubMed

pheochromocytoma perioperative management anesthesia

Reading File

Finding Sources

Reading File

I now have comprehensive, authoritative content from multiple textbooks. Let me compose the full MD Anaesthesia exam answer.

Pheochromocytoma: Pathophysiology, Diagnosis, and Anesthetic Management

1. DEFINITION AND EPIDEMIOLOGY

A pheochromocytoma is a vascular tumor of chromaffin tissue, most commonly of the adrenal medulla, that produces and secretes catecholamines (primarily norepinephrine, and to a lesser extent epinephrine and dopamine). It is the classic "10% tumor":

~10% are extra-adrenal (called paragangliomas - located at the organ of Zuckerkandl at the aortic bifurcation or carotid body)
~10% are bilateral (up to 50% in familial syndromes)
~10% are malignant (higher - up to 20% - in extra-adrenal sites). Note: Recent understanding recognizes all pheochromocytomas have malignant potential
~10% are not associated with hypertension
In a 25-year-old, always suspect a familial/genetic syndrome

Associated syndromes:

Multiple Endocrine Neoplasia (MEN) type IIa and IIb - via RET mutations
Von Hippel-Lindau (VHL) disease - VHL gene mutation
Neurofibromatosis type I - NF1 gene
Succinate dehydrogenase (SDH) subunit mutations

Miller's Anesthesia, 10e, p. 4239; Robbins & Kumar Basic Pathology, p. 762

2. PATHOPHYSIOLOGY

A. Tumor Origin and Catecholamine Synthesis

Pheochromocytomas arise from chromaffin cells of the neural crest. These cells are capable of synthesizing catecholamines via the tyrosine-dopamine-norepinephrine-epinephrine pathway. The tumor autonomously hypersecrets catecholamines, either tonically or in paroxysms.

Genetic mechanisms promoting carcinogenesis:

RET (MEN2) and NF1: enhance growth factor receptor signaling
VHL, SDH subunits, EPAS1: increased activity of hypoxia-inducible factors (HIFs)

B. Consequences of Catecholamine Excess

Receptor Stimulated	Pathophysiological Consequence
α1 (norepinephrine dominant)	Intense peripheral vasoconstriction → severe hypertension → intravascular volume depletion (hematocrit rises)
α1 sustained	Renal failure, cerebral hemorrhage, left ventricular hypertrophy
β1 (epinephrine dominant)	Tachycardia, increased automaticity, ventricular ectopy, increased myocardial work → ischemia and catecholamine-induced cardiomyopathy
β2	Vasodilation (partially offsets α1); hyperglycemia (decreased insulin + gluconeogenesis)
Prolonged excess	Catecholamine-induced cardiomyopathy, pulmonary edema, myocardial infarction, ventricular fibrillation, CVA

Volume depletion is a key feature - chronic vasoconstriction reduces plasma volume, and patients may have hematocrit ≥50%. This contributes to severe post-tumor-removal hypotension.

Catecholamine-induced cardiomyopathy (Takotsubo-like or dilated pattern) may exist preoperatively and significantly increases perioperative risk.

Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 460; Robbins & Kumar, p. 762

C. Gross and Microscopic Pathology

Gross: Yellow-tan, well-circumscribed lesion compressing adjacent adrenal cortex; larger tumors are hemorrhagic/necrotic/cystic. On exposure to potassium dichromate, the tumor turns dark brown (positive chromaffin reaction - catecholamine oxidation)
Microscopic: Polygonal to spindle-shaped chromaffin cells in "Zellballen" (cell-ball) nests supported by a rich vascular network; granular cytoplasm due to catecholamine-containing granules; electron microscopy shows membrane-bound, electron-dense secretory granules
Malignancy criterion: Only metastasis (lymph nodes, liver, lung, bone) confirms malignancy - capsular/vascular invasion and nuclear pleomorphism alone are insufficient

Robbins & Kumar Basic Pathology, p. 762

3. CLINICAL FEATURES

The classic triad is: episodic headache + sweating + palpitations/tachycardia

In a 25-year-old patient presenting with this triad, pheochromocytoma must be excluded.

System	Manifestation
Cardiovascular	Hypertension (sustained or paroxysmal), tachycardia, arrhythmias, angina, cardiomyopathy
Neurological	Severe headache (hypertensive), tremors, anxiety, panic attacks
Metabolic	Hyperglycemia, weight loss
Gastrointestinal	Nausea, vomiting, abdominal pain
Constitutional	Sweating, pallor, flushing

Paroxysmal episodes are triggered by: position changes, anxiety, exercise, medications (especially opioids, metoclopramide, tricyclics), tumor palpation, or induction of anesthesia.

When to suspect pheochromocytoma:

Any young (<20 years) hypertensive patient
Malignant or treatment-resistant hypertension
Classic "spells" even without sustained hypertension
Familial syndromes (MEN2, VHL, NF1)
Unexpected intraoperative hypertension + tachycardia during abdominal surgery

4. DIAGNOSIS

A. Biochemical Diagnosis

Test	Comment
24-hour urine fractionated metanephrines and catecholamines	Best initial screen in low suspicion patients; sensitivity and specificity >98%
Plasma fractionated metanephrines	Preferred in high suspicion (adrenal mass, familial syndrome); sensitivity 96-100%, specificity 85-89%
Urinary vanillylmandelic acid (VMA)	Classic test; less sensitive than metanephrines
Plasma/urine normetanephrine, metanephrine	Most sensitive overall
Clonidine suppression test	Used to clarify borderline plasma metanephrine elevations (normal: suppresses catecholamines; pheo: no suppression)

Diagnostic threshold: Plasma/urine free metanephrine concentrations >2x upper limit of normal are diagnostic for pheochromocytoma.

B. Localization (Imaging)

Modality	Notes
CT abdomen/pelvis	First-line; best anatomical detail; ~95% sensitivity for adrenal pheo
MRI	Preferred in children, pregnant patients, suspected extra-adrenal/metastatic disease; T2 bright signal characteristic
MIBG scintigraphy (I-123/I-131)	Functional imaging; highly specific; detects extra-adrenal and metastatic disease
PET scan (F-DOPA, F-FDG)	For MIBG-negative cases; increasing role

Miller's Anesthesia, 10e, p. 4240; Morgan & Mikhail, p. 460

5. PREOPERATIVE PREPARATION

This is the most critical phase. The goal is to control hypertension, restore intravascular volume, and optimize end-organ function (cardiac, renal) before surgery. Minimum preparation time: 10-14 days (some guidelines recommend longer).

A. Blood Pressure Control (Alpha Blockade First - MANDATORY)

Never start beta-blocker before alpha-blocker - this will cause unopposed alpha stimulation and worsen hypertension.

Drug	Dose	Notes
Phenoxybenzamine (non-selective, irreversible α-blocker)	Start 10 mg BD; titrate up	Most commonly used; long duration; prevents acute catecholamine surges
Prazosin (selective α1-blocker)	2-5 mg, 2-3 times/day	Alternative; shorter acting
Doxazosin (selective α1-blocker)	2-32 mg/day	Longer acting; once daily
Terazosin	2-5 mg/day	Alternative

Roizen Criteria for adequacy of alpha blockade (traditional):

Blood pressure <165/90 mmHg for 24-48 hours preoperatively
Orthostatic hypotension present but BP >80/45 mmHg standing
No ST-T changes on ECG for 1 week
<1 PVC per 5 minutes

Endocrine Society 2014 Guidelines (tighter targets):

BP <130/80 mmHg sitting; systolic >90 mmHg standing
Heart rate 60-70 bpm sitting, 70-80 bpm standing

B. Beta Blockade (Only After Adequate Alpha Blockade)

Add beta-blocker if: persistent tachycardia (HR >100 bpm), tachyarrhythmias, or target HR not achieved.

Atenolol, metoprolol, or propranolol (oral, long-term)
Esmolol (IV, short-acting, useful intraoperatively)

Propranolol also inhibits T4→T3 conversion (additional benefit).

C. Volume Repletion

High sodium diet (3-5 g/day) + liberal fluid intake to reverse catecholamine-induced volume contraction during alpha blockade
Oral hydration is preferred; IV preloading not shown to improve outcomes

D. Additional Agents

Agent	Role
Calcium channel blockers (nicardipine, amlodipine, nifedipine)	For patients intolerant of alpha blockade (profound orthostasis); also as adjunct; amlodipine shown effective as alternative to alpha blockade
Metyrosine (tyrosine hydroxylase inhibitor)	Reduces catecholamine synthesis by 50-80%; reserved for high-catecholamine states, metastatic disease, or inadequate BP control
IV phentolamine	For acute intraoperative hypertensive crises
Sodium nitroprusside or nicardipine	For intraoperative BP crises

E. Preoperative Assessment

ECG: Assess for LVH, arrhythmias, ischemic changes
Echocardiography: If catecholamine cardiomyopathy suspected
Renal function tests: BUN, creatinine
FBS/HbA1c: Hyperglycemia assessment
CBC: Hematocrit (elevated = volume depletion)
Electrolytes
Airway assessment (standard)

Miller's Anesthesia, 10e, p. 4241-4243

6. INTRAOPERATIVE MONITORING

A 25-year-old patient with pheochromocytoma requires the following monitoring:

Standard Monitors (ASA Minimum)

ECG (5-lead, continuous)
SpO2
Capnography (EtCO2)
Temperature

Mandatory Additional Monitors

Monitor	Rationale
Intra-arterial line (A-line) - placed preinduction	Beat-to-beat BP monitoring; essential for immediate response to catecholamine surges; radial artery preferred
Large-bore IV access (x2)	Rapid fluid resuscitation after tumor devascularization
Urinary catheter	Urine output monitoring; fluid status

Selective Advanced Monitoring

Monitor	When to Use
Central venous catheter (CVP)	When postoperative vasopressor infusions are anticipated; not routine
Transesophageal echocardiography (TEE)	When ventricular dysfunction or cardiomyopathy is present
Pulmonary artery catheter (PAC)	Reserved for severe ventricular dysfunction
BIS/depth of anesthesia monitor	Avoids light anesthesia triggering catecholamine surge

Drug Preparation (Ready Before Induction)

Phentolamine IV (for hypertensive crisis)
Sodium nitroprusside infusion (for sustained hypertension)
Nicardipine infusion
Esmolol infusion (for tachycardia/hypertension)
Norepinephrine/vasopressin (for post-ligation hypotension)
Lignocaine/amiodarone (for arrhythmias)
Dextrose infusion (hypoglycemia post-tumor removal)

7. ANESTHETIC MANAGEMENT

A. Premedication

Benzodiazepines (midazolam 1-2 mg IV) or dexmedetomidine for anxiolysis - reduces catecholamine surge from anxiety
Continue alpha and beta blockers until the morning of surgery
Avoid: metoclopramide (stimulates catecholamine release from tumor), atropine (tachycardia)

B. Induction

Goals: Slow, controlled, deep induction - avoid any stimulus that precipitates catecholamine surge

Step	Approach
Preoxygenation	3-5 min 100% O2
Induction agents	Propofol (1.5-2.5 mg/kg) or etomidate (0.2-0.3 mg/kg) - both safe
Avoid ketamine	Stimulates sympathetic nervous system, worsens hypertension and tachycardia
Opioid adjunct	Fentanyl (2-4 mcg/kg) or remifentanil - attenuates intubation response
Neuromuscular blockade	Vecuronium or rocuronium (first choice); avoid pancuronium (vagolytic, tachycardia) and atracurium (histamine release triggers catecholamines)
Laryngoscopy and intubation	Only after deep anesthesia; consider lidocaine 1.5 mg/kg IV 90 sec before intubation to blunt response
Airway: video laryngoscopy if anticipated difficult

C. Maintenance of Anesthesia

Agent	Suitability
Isoflurane, sevoflurane	Safe; do not sensitize myocardium to catecholamines
Desflurane	Avoid - causes transient sympathetic activation and tachycardia
Halothane	Avoid - sensitizes myocardium to arrhythmogenic effects of catecholamines
Propofol TIVA	Acceptable
N2O	Can be used; minimize in bowel surgery
Opioids	Fentanyl, sufentanil, remifentanil - all acceptable
Epidural (combined technique)	Useful for postoperative analgesia; does NOT reliably prevent intraoperative catecholamine crises (tumor still releases catecholamines despite sensory/sympathetic block); may cause post-ligation hypotension

Depth of anesthesia: Maintain adequate depth throughout; inadequate anesthesia is the most common cause of intraoperative hypertension.

D. Intraoperative Hemodynamic Management

Phase 1: Pre-tumor devascularization (before adrenal vein ligation) - expect hypertensive crises during:

Induction and intubation
Pneumoperitoneum (laparoscopy)
Surgical manipulation/handling of tumor
Positioning

Management of hypertensive crisis:

Drug	Dose	Onset
Phentolamine (IV α-blocker)	1-5 mg IV bolus, repeat PRN	1-2 min onset; 10-15 min duration; risk of reflex tachycardia
Sodium nitroprusside	0.5-8 mcg/kg/min infusion	Immediate onset; titratable; cyanide toxicity risk at high doses
Nicardipine	5-15 mg/hr infusion	Useful, predictable
Magnesium sulfate	40-60 mg/kg IV + infusion	Inhibits catecholamine release and peripheral vasoconstriction
Esmolol	0.5-1 mg/kg IV bolus, 50-300 mcg/kg/min infusion	For tachycardia; only after alpha blockade
Nitroglycerine	0.5-10 mcg/kg/min	For acute hypertensive episodes

Target BP: Avoid BP >160/90 mmHg; prevent myocardial ischemia, stroke, and pulmonary edema.

Phase 2: Post-tumor devascularization (after adrenal vein ligation) - expect severe hypotension:

Cause: Sudden loss of catecholamine support + residual alpha blockade + volume depletion
May be aggravated by epidural or neuraxial block

Management of hypotension:

Drug	Dose	Notes
Norepinephrine	0.1-2 mcg/kg/min	First-line vasopressor
Vasopressin	0.03-0.04 U/min	Useful when catecholamine receptors down-regulated
Phenylephrine	50-200 mcg IV boluses	Pure alpha agonist
IV fluid boluses	Crystalloid/colloid	Adequate pre-loading is key

Arrhythmia management:

Ventricular arrhythmias: lidocaine, amiodarone, esmolol
Atrial fibrillation: esmolol, amiodarone

E. Surgical Considerations

Laparoscopic (retroperitoneoscopic or transperitoneal) is preferred - less hemodynamic instability vs. open
Communicate surgical steps (tumor handling, vessel ligation) in real time with anesthesiologist
Pre-operative team briefing about blood pressure goals, fluid strategy, anticipated vasopressors

8. POSTOPERATIVE MANAGEMENT

Problem	Management
Hypotension (most common)	IV fluids; norepinephrine infusion; vasopressin; wean as volume restored
Hypoglycemia	Insulinoma-like effect after epinephrine withdrawal; monitor glucose hourly; dextrose infusion
Hypertension	Residual tumor (incomplete resection), pain, fluid overload; antihypertensives
Adrenal insufficiency (if bilateral adrenalectomy)	Hydrocortisone 100 mg IV every 8 hours
Pain	Multimodal analgesia; epidural if placed

ICU admission is standard for:

Hemodynamic instability
Bilateral adrenalectomy
Significant catecholamine cardiomyopathy
High-output or large tumor

Follow-up (within 2-6 weeks): Recheck 24-hour urinary catecholamines/metanephrines to confirm biochemical cure. Lifelong surveillance for recurrence or metachronous tumor.

9. SPECIAL CONSIDERATIONS FOR A 25-YEAR-OLD PATIENT

Genetic testing is mandatory - screen for MEN2, VHL, SDH mutations; family screening
Higher likelihood of extra-adrenal or bilateral disease compared with older patients
Potentially fertile female - exclude pregnancy (beta-HCG) before elective surgery
Generally good cardiac reserve - less likely to have pre-existing cardiomyopathy but not immune if catecholamine levels have been high chronically
Long life ahead - the 10-14 day preoperative preparation should not be shortened
If MEN2B: examine for marfanoid habitus, mucosal neuromas, medullary thyroid cancer - coordinate multidisciplinary surgery

SUMMARY TABLE: Key Drug Choices

Phase	Drug	Use
Preoperative	Phenoxybenzamine	Alpha blockade (first-line)
Preoperative	Atenolol/propranolol	Beta blockade (after alpha)
Preoperative	Metyrosine	Catecholamine synthesis inhibition
Induction	Propofol/etomidate	Safe induction agents
Induction	Avoid ketamine, halothane, pancuronium, atracurium
Intraoperative hypertension	Phentolamine, SNP, nicardipine, MgSO4	Crisis management
Post-ligation hypotension	Norepinephrine, vasopressin, IV fluids	Vasopressor support
Post-op hypoglycemia	Dextrose infusion	Glucose monitoring

References:

Miller's Anesthesia, 10th Edition, pp. 4239-4245
Morgan & Mikhail's Clinical Anesthesiology, 7th Edition, pp. 459-462
Robbins & Kumar Basic Pathology, pp. 761-763
Endocrine Society Clinical Practice Guideline 2014 (Lenders et al.)

This is a shared conversation. Sign in to Orris to start your own chat.